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Background: Sjogren’s syndrome (SS) is a chronic autoimmune disease mainly affecting salivary and lacrimal
glands. Current diagnostic criteria for SS utilize anti-Ro and anti-La as serological markers. Animal models for SS have
identified novel autoantibodies, anti-salivary gland protein 1 (SP1), anti-carbonic anhydrase 6 (CA6) and parotid
secretory protein (PSP). These novel antibodies are seen in the animals at an earlier stage of SS than anti-Ro and
anti-La. The current studies were designed to evaluate these novel autoantibodies in the sera of well-characterized
patients with dry eyes and dry mouth and lip biopsies from the Sjogren’s International Collaborative Clinical Alliance
(SICCA) to determine if they indeed identify SS with less severe disease than patients expressing anti-Ro and anti-La.
Methods: Sera were obtained from SICCA registry in patients for whom lymphocytic foci per 4 mm2 on the lip
biopsies was either 0 (F = 0), <1 (F <1) or > 3 (F >3). ELISA assays were utilized to evaluate these sera for anti-Ro,
anti-La, anti-SP1, anti-CA6, and anti-PSP.
Results: In patients with dry eyes and dry mouth but F = 0, increased expression of anti- CA6 was noted compared
to the F <1 group (p = .032) or the F > 3 group (p = .006). Neither anti-PSP nor anti-SP1 reached statistical significance
because of the small numbers in the F0 group, although there was a trend for their expression to be higher in the F0
group. On the other hand, the expression of anti-Ro was significantly reduced in the F0 group compared to the F <1
(p = .0021) and F > 3 (p = .0003) groups. The reduced expression of anti-La in the F0 group compared to the F <1 and
F > 3 groups did not quite reach statistical significance.
Conclusions: Anti-Ro and anti-La identify patients with SS and more severe disease than anti-SP1, anti-CA6, and
anti-PSP. More studies are needed to identify the timing in the course of SS when these different autoantibodies
are expressed and/or whether they are expressed in patients with different clinical manifestations.
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Sjogren’s syndrome (SS) is a common autoimmune dis-
ease characterized by dry eyes and dry mouth along with
associated clinical manifestations that can include inter-
stitial lung disease, kidney disease, neuropathy, vasculitis
and lymphoma [1,2]. Therapeutic trials in SS have em-
phasized the importance of early diagnosis for optimal* Correspondence: jambrus@buffalo.edu
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unless otherwise stated.response to therapy [3]. Current diagnostic criteria both
from the American College of Rheumatology and the
American-European Consensus Group utilize anti-Ro
and anti-La [4]. Several studies have emphasized the ex-
istence of many patients with SS lacking these markers.
Recently studies with animal models of SS have identi-
fied novel autoantibodies, anti-salivary gland protein 1
(SP1), anti-carbonic anhydrase 6 (CA6) and anti-parotid
secretory protein (PSP) [5]. These autoantibodies were
shown to be present in patients with SS as well as in
patients with idiopathic dry mouth and dry eyes [5,6].
The current studies were undertaken to investigate
expression of these autoantibodies in the sera ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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score (FS) measured from labial salivary glands and used as
a possible indicator of SS disease severity.
Methods
Sera
Sera were obtained along with demographics of the pa-
tients from the Sjogren’s International Collaborative
Clinical Alliance (SICCA). SICCA is an ongoing longitu-
dinal multi-site observational study that is studying a
large cohort of uniformly evaluated individuals from eth-
ically diverse populations. SICCA participants must be
at lest 21 years of age and have: a complaint of dry eyes
or dry mouth or a previous suspicion or diagnosis of SS
or elevated serum ANA, RF, SS-A, or SS-B, or bilateral
parotid enlargement in a clinical setting of SS, or a re-
cent increase in dental caries [7]. Patients signed in-
formed consent when participating in SICCA but did
not sign a specific informed consent for these studies.
Patients sera for this study were requested based on
FS, FS = 0, FS < 1 per 4 mm2 and FS > 3 per 4 mm2
to select patients with different degrees of salivary
gland inflammation.
Normal controls were obtained from donors in Buffalo,
New York lacking defined medical illnesses, dry eyes or
dry mouth. Of the patient groups studied the FS = 0 con-
tained 9 such patients of whom 4 were males and had a
mean age of 49.8 years. In the FS < 1 group there were 40
patients of whom 3 were male and there was a mean age
of 49.9 years. The FS > 3 group had 40 patients of whom 2
were males and had a mean age of 51 years. There were
50 normal controls that included 5 males with a mean age
of 37.5 years. Approval for these studies was obtained
from the Institutional Review Board, SUNY at Buffalo
School of Medicine.
Assays
Autoantibodies to SP1, PSP, CA-VI, Ro and La were de-
termined using ImmuLisa ELISAs (Immco Diagnostics
Inc., Buffalo, NY). In brief, kits contain micro-wells
coated with highly purified recombinant antigen (SP1 or
PSP or CA-VI or Ro or La) or native antigens (RF). 96
plate wells are blocked and stabilized by the manufac-
turer to reduce non-specific binding. Controls, calibra-
tors and diluted (1:100) patient serum are incubated in
the antigen-coated wells to allow specific binding of
autoantibodies to the antigen. Unbound serum compo-
nents are washed off and bound antibodies are detected
after incubations with anti-human IgG conjugated to
HRP (Horse Radish Peroxidase) and specific enzyme
substrate (TMB) as per manufacturer’s protocol. The
chromogenic reaction is stopped and the intensity of the
color change, which is proportional to the concentration
of the bound autoantibody, is read by a spectrophotometerat 450 nm. Results are expressed in ELISA units per
milliliter (EU/ml) using the calibrators provided in
the kit and reported as positive for a value > 20 or
negative for a value <20.
Statistics
Data were analyzed using unpaired student’s t tests with
Prism 6 software (GraphPad, La Jolla, CA).
Results and discussion
Studies utilizing the IL-14α transgenic (IL14aTG) mouse
model of SS demonstrated that loss of salivary gland
function occurs before infiltration of the submandibular
and lacrimal glands with lymphocytes [8,9]. Further-
more, anti-SP1 and anti-CA6 were demonstrated in the
sera of the mice at 6 months of age, a time in which sal-
ivary gland function was lost but no significant lympho-
cytic infiltration was noted in the glands [5]. We were
therefore interested in studying patients with dry eyes
and dry mouth lacking lymphocytic infiltration of the
salivary glands. The SICCA cohort contained 9 such pa-
tients with lip biopsies described as showing sclerosing
chronic sialoadenitis but no evidence of lymphocytic in-
filtration. The group contained 4 males and had a mean
age of 49.8 years. At the same time, we studied 40 sera
from patients with mild disease (focus score < 1 per
4 mm2) and 40 patients with moderate disease (focus
score > 3 per 4 mm2). The group with mild disease con-
tained 3 males and had a mean age of 49.9 years. The
group with moderate disease contained 2 males and had
a mean age of 51 years. There were 50 normal controls
that included 5 males with a mean age of 37.5 years.
Figure 1 demonstrates that in the patients with focus
score = 0, more patients expressed antibodies anti-SP1,
anti-CA6 and anti-PSP than anti-Ro and anti-La (6 vs 2).
In patients with mild (F <1) or moderate disease (F >3), the
majority of the patients expressed anti-Ro or anti-La while
fewer numbers of patient sera contained anti-SP1, anti-
CA6 and anti-PSP. In each of the study groups, F = 0, F <1
and F > 3, the expression of the autoantibodies, anti-CA6,
anti-PSP, anti-SP1, anti-Ro and anti-La, was statistically
significant when compared to the normal controls (in
all cases p < .0005). The increased expression of anti-
CA6 in the F0 group compared to the F <1 group
(p = .032) or the F > 3 group (p = .006) were statisti-
cally significant. Neither anti-PSP nor anti-SP1 reached
statistical significance because of the small numbers in
the F0 group, although there was a trend for their expres-
sion to be higher in the F0 group. On the other hand, the
expression of anti-Ro was significantly reduced in the
F0 group compared to the F <1 (p = .0021) and F > 3
(p = .0003) groups. The reduced expression of anti-La
in the F0 group compared to the F <1 and F > 3
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Figure 1 Sera were obtained from SICCA on patients with complaints of dry eyes and dry mouth who had lip biopsies with focus
scores = 0 (9 patients; 4 male, mean age 49.8 years), focus scores < 1 / 4 mm2 (40 patients; 3 male; mean age 49.9 years) or focus
scores > 3 / 4 mm 2 (40 patients; 2 males; mean age 51 years). Normal controls contained 5 males and had a mean age of 37.5 years
(50 patients). In the anti-CA6 studies, positives ranged from 20.7 – 46.4 and negatives from 0 – 19.6. In the anti-PSP studies, positives ranged from
20.3 – 99 and negatives from .1 – 14.6. In the anti-SP1 studies, positives ranged from 20.7 – 65.1 and negatives from 0 – 17.1. In the anti-Ro studies,
positives ranged from 26.2 – 330 and negatives from 1.1 – 16.6. In the anti-La studies, positives ranged from 20.9 – 195. 4 and negatives from
0.9 – 19.6. In each of the study groups, F = 0, F <1 and F > 3, the expression of the autoantibodies, anti-CA6, anti-PSP, anti-SP1, anti-Ro and anti-La,
was statistically significant when compared to the normal controls (in all cases p < .0005). The increased expression of anti- CA6 in the F0 group
compared to the F <1 group (p = .032) or the F > 3 group (p = .006) were statistically significant. Neither anti-PSP nor anti-SP1 reached statistical
significance because of the small numbers in the F0 group, although there was a trend for their expression to be higher in the F0 group. On the
other hand, the expression of anti-Ro was significantly reduced in the F0 group compared to the F <1 (p = .0021) and F > 3 (p = .0003) groups. The
reduced expression of anti-La in the F0 group compared to the F <1 and F > 3 groups did not quite reach statistical significance.
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lacking anti-Ro or anti-La. In the F <1 group 3 patients
lacked anti-Ro or anti-La while in the F > 3 group 6 pa-
tients lacked these autoantibodies. Figure 2 demonstrates
that in the anti-Ro or anti-La negative patients, most
patients expressed anti-SP1, anti-CA6 or anti-PSP, al-
though there were a few patients who expressed
none of these autoantibodies in the focus score = 0
and the moderate groups. Because of the small num-
bers, these observations do not reach statistical sig-
nificance. More patients need to be studied to confirm
these trends.
Our understanding of the pathophysiology of SS is
currently in flux. While early models of SS had sug-
gested a disease largely driven by the adaptive immune
system, more recent models have implicated the role of
the innate immune system in the initiation of the disease
[10]. Of note, in the IL14aTG model for SS the innate
immune system is responsible for the majority of the de-
struction of the salivary and lacrimal glands [11,12].
Lymphocytes are found in the salivary and lacrimal
glands only after significant loss of salivary gland func-
tion [12]. In this model, antibodies anti-SP1, anti-CA6and anti-PSP occur during this early stage of disease,
while antibodies anti-Ro and anti-La occur later in the
disease course [5].
The data presented in this manuscript suggest that
patients with low FS on salivary gland biopsies express
anti-SP1, anti-CA6 and anti-PSP more frequently than
anti-Ro and anti-La, just like the IL14aTG mice. The
FS = 0 group, however, does not meet full criteria for
SS, so they would not officially be given that designa-
tion. There are no data available to determine whether
this group ever will meet full SS criteria. Previously
published studies have shown frequent expression of
anti-SP1 in patients with idiopathic dry eyes and dry
mouth for less than 2 years [5]. What is unclear from
this work is how many of these patients in time will
meet full criteria for SS and how many of these patients
will not progress further.
Interestingly, a recent study from Jonsson et al. dem-
onstrated the existence of anti-Ro or anti-La in the sera
of patients often before they developed clinical evidence
of SS [13]. Similar finding were made in a previous study
in SLE [14]. Many patients who developed SS, however,
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Figure 2 Patients from the SICCA Cohort lacking antibodies anti-Ro or anti-La were evaluated for their expression of anti-SP1, anti-CA6
and anti-PSP. In the focus score = 0 group there were 7 patients, in the focus score < 1 / 4 mm2 there were 3 patients and in the focus
score > 3 / 4 mm2 there were 6 patients. Data shown are the percentage of patients positive for the designated autoantibodies. The
patient numbers are too small for statistical significance to occur in the differences between the expression of the various autoantibodies.
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studies.
One of the novel aspects of the antigens SP1, CA6
and PSP compared to Ro and La is that they are
found selectively in the salivary and lacrimal glands.
Ro and La are found virtually in every cell. It is un-
clear why antibodies anti-Ro and anti-La should be
specific for SS, and in fact they are found in SLE
and various other autoimmune diseases. Perhaps cer-
tain types of cellular injury are necessary before anti-
bodies anti-Ro and anti-La appear. It has been
postulated that SP1, CA6 and PSP may have roles in
the adherence and/or clearance of various infections
[15]. If this were in fact the case, it would be logical
to suspect that a hapten-carrier system established
with an infectious agent could lead to the develop-
ment of antibodies to these antigens. If we postulate
that SS is initiated by infections in the salivary and
lacrimal glands, production of antibodies anti-SP1,
anti-CA6 and anti-PSP early in the course of disease
would make sense.
The role of autoantibodies in SS is currently poorly
understood. While vaccination of mice with Ro results
in salivary gland injury and anti-Ro antibodies, it is un-
clear whether the anti-Ro antibodies participate in the
salivary gland injury, are part of a reparative mechanism
for the injury and/or are merely a marker for disease
[16]. Attempts have been made to correlate autoanti-
bodies with particular disease manifestations in SS,
such as anti-carbonic anhydrase 2 antibodies with renaltubular acidosis, however no direct link has been made
between the autoantibodies and tissue dysfunction [17].
Similarly, the anti-SP1, anti-CA6 and anti-PSP anti-
bodies are currently evaluated only as markers of
disease. Future studies will need to investigate their
significance.
While these studies suggest that anti-SP1, anti-CA6
and anti-PSP are early markers for SS, future studies will
have to evaluate these autoantibodies in other cohorts of
patients. It will be necessary to determine the long-term
consequences of expression of these autoantibodies in
particular patients and “normal controls”. These auto-
antibodies may denote particular stages of SS and/or
particular forms of SS.Conclusions
Novel autoantibodies, anti-SP1, anti-CA6 and anti-PSP,
identify patients with dry eyes and dry mouth and low
focus scores on lip biopsies while anti-Ro and anti-La,
which are currently in the diagnostic criteria for Sjogren’s
syndrome occur more in patients with high focus scores
on lip biopsy than in patients with low focus scores on lip
biopsy.
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